Antibody–drug conjugates targeting RON receptor tyrosine kinase as a novel strategy for treatment of triple-negative breast cancer
Author:
Publisher
Elsevier BV
Subject
Drug Discovery,Pharmacology
Reference84 articles.
1. Breast cancer treatment: a review;Waks;JAMA,2019
2. Insights into molecular classifications of triple-negative breast cancer: improving patient selection for treatment;Garrido-Castro;Cancer Discov.,2019
3. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease;Bianchini;Nat. Rev. Clin. Oncol.,2016
4. A novel putative receptor protein tyrosine kinase of the met family;Ronsin;Oncogene,1993
5. RON is a heterodimeric tyrosine kinase receptor activated by the HGF homologue MSP;Gaudino;EMBO J.,1994
Cited by 8 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Oroxylin A suppresses breast cancer-induced osteoclastogenesis and osteolysis as a natural RON inhibitor;Phytomedicine;2024-07
2. Exploring the therapeutic potential of ADC combination for triple-negative breast cancer;Cellular and Molecular Life Sciences;2023-11-06
3. Exploring the therapeutic potential of ADC combination for triple-negative breast cancer;2023-04-19
4. Defining the Emergence of New Immunotherapy Approaches in Breast Cancer: Role of Myeloid-Derived Suppressor Cells;International Journal of Molecular Sciences;2023-03-08
5. Antibody–drug conjugates: the evolving field of targeted chemotherapy for breast cancer treatment;Therapeutic Advances in Medical Oncology;2023-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3